Corcept Therapeutics

Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals

Retrieved on: 
Thursday, December 8, 2022
Prostate, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Microdeletion syndrome, Ovary, Hyperglycemia, Judgement, Liver disease, United States district court, Federal Trade Commission, Food, ALS, FDA, Abbreviated New Drug Application, NASH, Wilms' tumor, Court, United States federal executive departments, DOJ, Prediabetes, Amyotrophic lateral sclerosis, MD, Fatty liver disease, CORT, ANDA, Patent, Weight gain, Patient, Corcept Therapeutics, FTC, Pharmaceutical industry

In connection with the settlement, Corcept has granted Hikma the right to sell a generic version of Korlym in the United States beginning October 1, 2034 or earlier under circumstances customary for settlement agreements of this type.

Key Points: 
  • In connection with the settlement, Corcept has granted Hikma the right to sell a generic version of Korlym in the United States beginning October 1, 2034 or earlier under circumstances customary for settlement agreements of this type.
  • “It is gratifying to put an end to this litigation,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
  • As required by law, Corcept and Hikma will submit the agreement to the United States Federal Trade Commission (FTC) and the United States Department of Justice (DOJ) for review.
  • Similar patent litigation brought by Corcept against Teva Pharmaceuticals USA, Inc. remains pending.

Corcept Therapeutics Provides Miricorilant Clinical Development Update

Retrieved on: 
Thursday, December 8, 2022
Prostate, Ovary, Liver, Intellectual property, Hunting, Liver disease, Food, Journal of Clinical Psychopharmacology, ALS, Probability, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASH, Wilms' tumor, Doctor of Pharmacy, Fatty liver disease, CORT, Weight gain, COVID-19, Patient, Corcept Therapeutics, Pharmaceutical industry

“Miricorilant did not reverse AIWG in either our GRATITUDE or GRATITUDE II trials,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.

Key Points: 
  • “Miricorilant did not reverse AIWG in either our GRATITUDE or GRATITUDE II trials,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • “Miricorilant continues to demonstrate great promise as a treatment for NASH,” added Dr. Guyer.
  • In this press release, forward-looking statements include those concerning the development of miricorilant, including its clinical attributes, regulatory approvals, mandates and oversight, and other requirements; our trials involving miricorilant, including their design, results and probability of success.
  • We disclaim any intention or duty to update forward-looking statements made in this press release.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Friday, December 16, 2022
Class Action Lawsuit, Professional Services, Legal, Light, Certification, CORT, Ethics, Suite, Corcept Therapeutics, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Thursday, December 15, 2022
Class Action Lawsuit, Professional Services, Legal, Light, Certification, CORT, Ethics, Suite, Corcept Therapeutics, Security (finance)

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (Corcept or the Company) (NASDAQ: CORT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 3, 2022
Progression-free survival, Exercise, Weight gain, Fatigue, Neck, Investment, Ageing, CORT, Food, Doctor of Pharmacy, Cushing's syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Irritability, Muscle, Investor, Intellectual property, NASH, Safety, Neuroinflammation, COVID-19, PIN, Marketing, Intention, Income, Ovary, NDA, Life expectancy, Physician, GRACE, ALS, Prostate, Clinical trial, Depression, Liver disease, NASDAQ, Microdeletion syndrome, Acquisition, Woman, Anxiety, Diabetes, Goal, Wilms' tumor, Insurance, Enrollment, SEC, Patient, MD, Pharmaceutical industry, Corcept Therapeutics

Net income was $34.6 million in the third quarter of 2022, compared to $30.5 million in the third quarter of 2021.

Key Points: 
  • Net income was $34.6 million in the third quarter of 2022, compared to $30.5 million in the third quarter of 2021.
  • Diagnosing and treating patients with a complex disease such as Cushings syndrome requires frequent in-person contact with physicians.
  • Our revenue in the third quarter was affected by fewer than expected in-person interactions as many physician practices have not returned to pre-pandemic patterns of activity.
  • Korlym is an excellent treatment for patients with Cushings syndrome and there are many eligible patients who have yet to receive it.

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on: 
Thursday, October 27, 2022
CORT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Amyotrophic lateral sclerosis, Liver disease, Food, Patient, Prostate, GLOBE, PIN, Corcept Therapeutics, Weight gain, ALS, Wilms' tumor, Ovary, Pharmaceutical industry

MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2022.

Key Points: 
  • MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2022.
  • The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
  • Participants must register in advance of the conference call by clicking here .
  • Corcepts drug Korlym was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushings syndrome.

Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Tuesday, October 11, 2022
Quality of life, Doctor of Pharmacy, SEC, Liver disease, NASDAQ, Patient, University Medical Center Utrecht, Amyotrophic lateral sclerosis, ALS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Goal, Probability, ALS Functional Rating Scale - Revised, Neurology, Corcept Therapeutics, Intention, Weight gain, Safety, Neuroinflammation, GLOBE, Intellectual property, Muscle, CORT, COVID-19, Pharmaceutical industry

"We are excited to initiate this important study in collaboration with TRICALS, the leading ALS academic consortium in Europe."

Key Points: 
  • "We are excited to initiate this important study in collaboration with TRICALS, the leading ALS academic consortium in Europe."
  • "I am excited to partner with Corcept to study dazucorilant's potential to significantly improve treatment outcomes for people living with ALS."
  • DAZALS is a 198-patient, randomized, double-blind, placebo-controlled Phase 2 trial of dazucorilant in patients with ALS.
  • We disclaim any intention or duty to update forward-looking statements made in this press release.

Alcohol Use Disorder Market to Witness Positive Growth at a CAGR of 8.8% by 2032 | DelveInsight

Retrieved on: 
Wednesday, September 28, 2022
Memantine, New, Social stigma, GHB, Perspiration, Compliance, ASP, Topiramate, Lists of diseases, Patient, Disulfiram, United Kingdom, Benzodiazepine, Astellas Pharma, National Institute, AUD, Psychiatric and mental health nursing, Prevalence, GABAB, Knowledge, Biomarker, Growth, Acamprosate, Alcoholism, Attention, Otsuka Pharmaceutical, Diagnostic and Statistical Manual of Mental Disorders, Drinking, ALKS, Health care, SMO, Gabapentin, Seizure, Corcept Therapeutics, Diagnosis, Hope, Population, Baclofen, Sodium oxybate, DSM, CORT, DSM-IV, LAS, VIVITROL, Mood Swings, National Institute on Alcohol Abuse and Alcoholism, Aripiprazole, Therapy, ALKS 3831, US FDA, DSM-V, Varenicline, Novo Nordisk, Pharmaceutical industry, Lithium, Alkermes, Ondansetron

LAS VEGAS, Sept. 28, 2022 /PRNewswire/ --DelveInsight's Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • Leading alcohol use disordercompanies such as Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others are developing novel alcohol use disorder drugs that can be available in the alcohol use disorder market in the upcoming years.
  • DelveInsight estimates that there were approximately 25 million 12-month diagnosed prevalent cases of alcohol use disorder in the 7MM in 2021.
  • TOPAMAX (topiramate) is even recommended for alcohol use disorder treatment by the National Institute on Alcohol Abuse and Alcoholism.
  • Moreover, because of the change in alcohol use disorder diagnostic criteria from DSM-IV to DSM-V, country-specific epidemiologic data on diagnosis, severity, and treatment are scarce and thus limiting the alcohol use disorder market growth.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Discover, Mercury, and Fulgent and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, September 17, 2022
Transfer, Consumer, HIPAA, Health Insurance Portability and Accountability Act, Remuneration, Discover Financial, Stark, NYSE, Sale, Securities Exchange Act of 1934, CFPB, Corcept Therapeutics, DFS, U.S. Securities and Exchange Commission, DOJ, Company, Acquisition, Electronic Fund Transfer Act, News, Glass house, Mercury, Therapy, Mercury Systems, Exchange, District, Genetics, Anti-Kickback Statute, Record, NASDAQ, GLOBE, SEC, Accountability Act, CORT, MRCY, Physical optics, Battle of Saint-Fulgent, Online gambling, Audit, Bank, Pharmaceutical industry, P.C, Discover

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Corcepts stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.
  • For more information on the Fulgent investigation go to: https://bespc.com/cases/FLGT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Medallion, RBB, Agrify, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, September 12, 2022
HIPAA, RBB, Sale, Royal Business Bank, Corcept Therapeutics, U.S. Securities and Exchange Commission, Company, News, Therapy, HuffPost, CEO, District, Record, NASDAQ, Alpha, GLOBE, SEC, Accountability Act, EVP, CORT, Medal, Health Insurance Portability and Accountability Act, Online gambling, Animal, Audit, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.